Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
5,574,695
-
Shares change
-
+592,280
-
Total reported value, excl. options
-
$35,452,254
-
Value change
-
+$4,184,678
-
Put/Call ratio
-
4.7%
-
Number of buys
-
37
-
Number of sells
-
-25
-
Price
-
$6.36
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q2 2018
82 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q2 2018.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,574,695 shares
.
Largest 10 shareholders include VANGUARD GROUP INC (1,206,754 shares), D.A. DAVIDSON & CO. (656,527 shares), Advisor Group, Inc. (612,964 shares), BlackRock Inc. (588,308 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (357,793 shares), Benchmark Capital Advisors (221,700 shares), EAM Investors, LLC (218,429 shares), GEODE CAPITAL MANAGEMENT, LLC (202,563 shares), EAM Global Investors LLC (164,511 shares), and GROUP ONE TRADING, L.P. (108,491 shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.